These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22013121)

  • 21. A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment.
    Rockx B; Bossart KN; Feldmann F; Geisbert JB; Hickey AC; Brining D; Callison J; Safronetz D; Marzi A; Kercher L; Long D; Broder CC; Feldmann H; Geisbert TW
    J Virol; 2010 Oct; 84(19):9831-9. PubMed ID: 20660198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection.
    Freiberg AN; Worthy MN; Lee B; Holbrook MR
    J Gen Virol; 2010 Mar; 91(Pt 3):765-72. PubMed ID: 19889926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging tropical diseases in Australia. Part 5. Hendra virus.
    Tulsiani SM; Graham GC; Moore PR; Jansen CC; Van Den Hurk AF; Moore FA; Simmons RJ; Craig SB
    Ann Trop Med Parasitol; 2011 Jan; 105(1):1-11. PubMed ID: 21294944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factsheet: Hendra virus.
    N S W Public Health Bull; 2011 Sep; 22(7-8):160-1. PubMed ID: 21982262
    [No Abstract]   [Full Text] [Related]  

  • 25. Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro.
    Aljofan M; Sganga ML; Lo MK; Rootes CL; Porotto M; Meyer AG; Saubern S; Moscona A; Mungall BA
    Virol J; 2009 Nov; 6():187. PubMed ID: 19889218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Henipavirus Encephalitis: Recent Developments and Advances.
    Ong KC; Wong KT
    Brain Pathol; 2015 Sep; 25(5):605-13. PubMed ID: 26276024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy.
    Porotto M; Orefice G; Yokoyama CC; Mungall BA; Realubit R; Sganga ML; Aljofan M; Whitt M; Glickman F; Moscona A
    J Virol; 2009 May; 83(10):5148-55. PubMed ID: 19264786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology of henipavirus disease in humans.
    Luby SP; Gurley ES
    Curr Top Microbiol Immunol; 2012; 359():25-40. PubMed ID: 22752412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge.
    Lo MK; Feldmann F; Gary JM; Jordan R; Bannister R; Cronin J; Patel NR; Klena JD; Nichol ST; Cihlar T; Zaki SR; Feldmann H; Spiropoulou CF; de Wit E
    Sci Transl Med; 2019 May; 11(494):. PubMed ID: 31142680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The changing face of the henipaviruses.
    Croser EL; Marsh GA
    Vet Microbiol; 2013 Nov; 167(1-2):151-8. PubMed ID: 23993256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infection and disease in reservoir and spillover hosts: determinants of pathogen emergence.
    Daniels PW; Halpin K; Hyatt A; Middleton D
    Curr Top Microbiol Immunol; 2007; 315():113-31. PubMed ID: 17848063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of Nipah and Hendra viruses with an historical aside.
    Ksiazek TG; Rota PA; Rollin PE
    Virus Res; 2011 Dec; 162(1-2):173-83. PubMed ID: 21963678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction: Nipah virus--discovery and origin.
    Chua KB
    Curr Top Microbiol Immunol; 2012; 359():1-9. PubMed ID: 22782307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge.
    Bossart KN; Geisbert TW; Feldmann H; Zhu Z; Feldmann F; Geisbert JB; Yan L; Feng YR; Brining D; Scott D; Wang Y; Dimitrov AS; Callison J; Chan YP; Hickey AC; Dimitrov DS; Broder CC; Rockx B
    Sci Transl Med; 2011 Oct; 3(105):105ra103. PubMed ID: 22013123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.
    Defang GN; Khetawat D; Broder CC; Quinnan GV
    Vaccine; 2010 Dec; 29(2):212-20. PubMed ID: 21050901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model.
    Guillaume V; Wong KT; Looi RY; Georges-Courbot MC; Barrot L; Buckland R; Wild TF; Horvat B
    Virology; 2009 May; 387(2):459-65. PubMed ID: 19328514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection.
    de Wit E; Williamson BN; Feldmann F; Goldin K; Lo MK; Okumura A; Lovaglio J; Bunyan E; Porter DP; Cihlar T; Saturday G; Spiropoulou CF; Feldmann H
    Antiviral Res; 2023 Aug; 216():105658. PubMed ID: 37356729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Nipah virus infections].
    Kai C
    Nihon Naika Gakkai Zasshi; 2004 Nov; 93(11):2341-6. PubMed ID: 15624469
    [No Abstract]   [Full Text] [Related]  

  • 39. Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus.
    Aljofan M; Porotto M; Moscona A; Mungall BA
    J Virol Methods; 2008 Apr; 149(1):12-9. PubMed ID: 18313148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Henipavirus membrane fusion and viral entry.
    Aguilar HC; Iorio RM
    Curr Top Microbiol Immunol; 2012; 359():79-94. PubMed ID: 22427111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.